Skip to main content
SpringerLink
Log in

Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Bisphosphonates (BisP) are non-metabolized compounds with high bone affinity used in bone metastasis diagnosis and treatment. Currently, BisP are used to treat hypercalcemia of malignancy as well as to prevent, minimize, or delay skeletal morbidity. These compounds have a long half-life in bone. Thus long-term BisP treatment might saturate bone and interfere with a single-dose scanning agent used for bone scintigraphy when visualizing bone metastases. In an effort to answer this question, this study evaluated the concordance of histology and Technetium99 methylene diophosphonate (Tc99 MDP) bone scintigraphy in the diagnosis of bone metastases in prostate cancer patients. We assessed the concordance of findings between bone scintigraphy and histology using 188 bone biopsies from 11 autopsied patients who died with metastatic prostate cancer, 5 of whom were treated with pamidronate for 2 to 13 months before death. Overall agreement between histology and bone scintigraphy was 84%, 86% in non-pamidronate-treated patients and 82% in pamidronate-treated patients. Scintigraphic bone metastases without histological metastasis (false negatives = 12.7%) were observed in 24 anatomic locations; half of these were in one patient who had been treated with pamidronate and had no histological bone response to the carcinoma. There were only 4 sites where a positive bone scan was not associated with histologic metastasis (false positives = 2.21%). There was no statistical difference between the treated and non-treated group for concordance, specificity, sensitivity, positive and negative predictive values of bone scintigraphy and prevalence of histological abnormality. Long-term pamidronate treatment of prostate cancer bone metastases does not generally affect the ability to detect bone metastases with Tc99 MDP bone scintigraphy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Galasko CS. Skeletal metastases. Clin Orthop 1986; 18–30.

  2. Ron IG, Striecker A, Lerman H et al. Bone scan and bone biopsy in the detection of skeletal metastases. Oncol Rep 1999; 6: 185–8.

    PubMed  CAS  Google Scholar 

  3. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961–78.

    Article  PubMed  CAS  Google Scholar 

  4. Lipton A. Bisphosphonates and breast carcinoma: Present and future. Cancer 2000; 88: 3033–7.

    Article  PubMed  CAS  Google Scholar 

  5. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in multiple myeloma. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2002; 20: 3719–36.

    Article  PubMed  Google Scholar 

  6. Saad F, Gleason DM, Murray R et al. A randomized, placebocontolled Trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: in press.

  7. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001; 31: 62–8.

    Article  PubMed  CAS  Google Scholar 

  8. Clarke NW, McClure J, George NJ. The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scand J Urol Nephrol 1993; 27: 475–83.

    Article  PubMed  CAS  Google Scholar 

  9. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948–55.

    Article  PubMed  CAS  Google Scholar 

  10. Roudier MP, True LT, Higano CS et al. Functional and clonal heterogeneity of bone metastatic prostate cancer. J Urol 2002; 165: 291–2.

    Google Scholar 

  11. Jacobson AF, Stomper PC, Cronin EB et al. Bone scans with one or two new abnormalities in cancer patients with no known metastases: Reliability of interpretation of initial correlative radiographs. Radiology 1990; 174: 503–7.

    PubMed  CAS  Google Scholar 

  12. Paulson DF. Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. Urology 1980; 15: 537–41.

    Article  PubMed  CAS  Google Scholar 

  13. Gulenchyn KY, Papoff W. Technetium-99m MDP scintigraphy. An insensitive tool for the detection of bone marrow metastases. Clin Nucl Med 1987; 12: 45–6.

    PubMed  CAS  Google Scholar 

  14. Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 181–6.

    PubMed  CAS  Google Scholar 

  15. McCarthy EF. Histopathologic correlates of a positive bone scan. Semin Nucl Med 1997; 27: 309–320.

    Article  PubMed  CAS  Google Scholar 

  16. Galasko CS. The pathological basis for skeletal scintigraphy. J Bone Joint Surg Br 1975; 57: 353–9.

    PubMed  CAS  Google Scholar 

  17. Galasko CS. Detection of bone metastases. Br Med J 1977; 1: 1537.

    Article  PubMed  CAS  Google Scholar 

  18. Masarachia P, Weinreb M, Balena R et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996; 19: 281–90.

    Article  PubMed  CAS  Google Scholar 

  19. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269–80.

    PubMed  CAS  Google Scholar 

  20. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol 2001; 28: 4–10.

    Article  PubMed  CAS  Google Scholar 

  21. Watt I, Hill P. Effects of acute administration of ethane hydroxydiphosphonate (EHDP) on skeletal scintigraphy with technetium-99m methylene diphosphonic acid (Tc-MDP) in the rat. Br J Radiol 1981; 54: 592–6.

    Article  PubMed  CAS  Google Scholar 

  22. Krasnow AZ, Collier BD, Isitman AT et al. False-negative bone imaging due to etidronate disodium therapy. Clin Nucl Med 1988; 13: 264–267.

    PubMed  CAS  Google Scholar 

  23. Ryan PJ, Gibson T, Fogelman I. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone. J Nucl Med 1992; 33: 1589–93.

    PubMed  CAS  Google Scholar 

  24. Sandler ED, Parisi MT, Hattner RS. Duration of etidronate effect demonstrated by serial bone scintigraphy. J Nucl Med 1991; 32: 1782–4.

    PubMed  CAS  Google Scholar 

  25. Carrasquillo JA, Whatley M, Dyer V et al. Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. J Nucl Med 2001; 42: 1359–63.

    PubMed  CAS  Google Scholar 

  26. Pecherstorfer M, Schilling T, Janisch S et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993; 34: 1039–44.

    PubMed  CAS  Google Scholar 

  27. Macro M, Bouvard G, Le Gangneux E et al. Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTchydroxymethylene bisphosphonate bone scintigraphy. A prospective study. Rev Rhum Engl Ed 1995; 62: 99–104.

    PubMed  CAS  Google Scholar 

  28. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890–4.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Urology, University of Washington, Seattle, Washington, USA

    M.P. Roudier, S.H. King & R.L. Vessella

  2. Radiology, University of Washington, Seattle, Washington, USA

    H. Vesselle

  3. Pathology, University of Washington, Seattle, Washington, USA

    L.D. True

  4. Oncology, University of Washington, Seattle, Washington, USA

    C.S. Higano

  5. Medicine and Endocrynology, University of Washington, Seattle, Washington, USA

    S.M. Ott

  6. Puget Sound VA Medical Center, Seattle, Washington, USA

    S.M. Ott & R.L. Vessella

Authors
  1. M.P. Roudier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Vesselle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L.D. True
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C.S. Higano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S.M. Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S.H. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R.L. Vessella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M.P. Roudier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roudier, M., Vesselle, H., True, L. et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20, 171–180 (2003). https://doi.org/10.1023/A:1022627421000

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022627421000

Search

Navigation